Lupin Limited (“Lupin”), a leading Indian pharmaceutical company, announced on 24 July 2015 that it has entered into a strategic asset purchase agreement with Temmler Pharma GmbH & Co. KG (“Temmler”) to acquire Temmler's specialty product portfolio. Temmler is part of the Aenova Group, a worldwide leading pharmaceutical contract manufacturer. Completion of the transaction is subject to customary closing conditions. Hengeler Mueller is advising Lupin on the transaction.
The Hengeler Mueller team is led by partner Daniela Favoccia (Corporate/M&A, Frankfurt) and counsel Patrick H. Wilkening (M&A, Düsseldorf) and includes partners Dirk Uwer (Regulatory, Düsseldorf) and Christian Hoefs (Labour, Frankfurt), counsel Andrea Schlaffge (IP, Düsseldorf) as well as associates Daniel A. Spitze, Abhijit Narayan (both Corporate/M&A), Anne Broll (Labour) (all Frankfurt), Lars Mesenbrink (Antitrust), Susanne Koch and Alla Drößler (both Regulatory) (all Düsseldorf).
